NASDAQ$UPB
Upstream Bio Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
Upstream Bio reported Q3 2025, revenue of $683K, a net loss of $33.7M.
For Q3 2025, Upstream Bio reported revenue of $683K, a net loss of $33.7M. Management discusses operating trends, liquidity, and priorities as disclosed in the filing.
- Revenue $683K.
- Net loss $33.7M.
- Upstream Bio updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Upstream Bio Inc · Revenue · Quarterly
$683K
Forward guidance
The filing discusses Upstream Bio's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Upstream Bio cites execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
- Pipeline milestones and cash runway remain key value drivers.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
- Clinical-stage or pre-commercial spend continues ahead of revenue scale.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q3 2025
+0.8%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.5%
Avg return
30 days after
67%
4 / 6 earnings
Positive
+7.9%
Q2 2025
Best reaction
-5.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.5% | -8.4% | — | |
| Q1 2026 | +4.7% | -5.3% | -31.9% | |
| Q3 2025 | -4.3% | -6.2% | +10.8% | |
| Q2 2025 | +7.9% | +7.0% | +28.8% | |
| Q1 2025 | -5.4% | +1.6% | +24.8% | |
| Q3 2024 | +1.7% | -0.7% | -10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro